Mardjan Dabir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mardjan Dabir has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Christina Antke
Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, 40225 Düsseldorf, Germany
2 shared publications - Dominik Schmitt
Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, 40225 Düsseldorf, Germany
2 shared publications - Eduards Mamlins
Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany
2 shared publications - Emil Novruzov
Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
2 shared publications - Frederik Lars Giesel
Department of Nuclear Medicine, University Hospital Düsseldorf, 40225 Düsseldorf, Germany
2 shared publications - Yuriko Mori
Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany
2 shared publications
Latest Publications
- Open Access
Head-to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [18F]FAPI-74 with [18F]FDG in Patients with PDAC: A Prospective Exploratory Study
Background: Radiolabeled fibroblast activation protein (FAP) ligands, a novel class of tracers for PET/CT imaging, have demonstrated very promising results in various oncological, as well as in some benign, diseases with long-term potential to supplant the current pan-cancer agent [18F]FDG in some cancer types. Pancreatic ductal carcinoma (PDAC) belongs to the group of epithelial malignancies with a strong so-called “desmoplastic reaction”, leading to a prominent tumor stroma with cancer-associated fibroblasts that exhibit a marked overexpression of fibroblast activation protein (FAP). The first clinical experiences in PDAC with 68Ga-labeled FAP ligands suggested superior sensitivity to [18F]FDG. However, there is limited data with 18F-labeled FAP derivatives, i.e. [18F]FAPI-74, yet prospective single- and multicenter trials are already ongoing. In this proof-of-concept study, we sought to evaluate the biodistribution, tumor uptake, and lesion detectability in patients with PDAC using [18F]FAPI-74 PET/CT as compared to [18F]FDG PET/CT scans for staging. Methods: This study includes 7 patients (median age 69) who underwent both [18F]FDG PET/CT with contrast-enhancement and [18F]FAPI-74 PET with low-dose CT for primary staging (n = 3) and therapy response control after neoadjuvant (n = 1) or re-staging after palliative therapy (n = 3). The mean interval between PET scans was 11 ± 4 days (range 1–15 days). The [18F]FDG and [18F]FAPI-74 PET/CT scans were acquired at 64 ± 4.1 min (range 61–91 min) and 66.4 ± 6.3 min (range 60–76 min), respectively, after administration of 200 ± 94 MBq (range 79–318 MBq) and 235 ± 88 MBq (range 90–321 MBq), respectively. Quantification of tracer uptake was determined with SUVmax and SUVmean. Furthermore, the tumor-to-background ratio (TBR) was derived by dividing the SUVmax of tumor lesions by the SUVmax of adipose tissue, skeletal muscle, and blood pool. Results: Overall, 32 lesions were detected in 7 patients including primary (n = 7), lung (n = 7), bone (n = 3), lymph node (n = 13), and peritoneal metastases (n = 2). [18F]FAPI-74 detected 22% more lesions compared with [18F]FDG with a better TBR and visual lesion delineation. In one patient the primary lesion could be detected unequivocally with [18F]FAPI-74 but was missed by [18F]FDG imaging. Altogether, most of the lesions demonstrated markedly elevated uptake of [18F]FAPI-74 with a simultaneous lower uptake in the background, providing a very high visual contrast. Conclusion: To the best of our knowledge, this is the first, prospective, intra-individual investigation comparing [18F]FAPI-74 with [18F]FDG imaging in PDAC with encouraging results. These pivotalresults supporta larger, multicentric, prospective study to determine the value of [18F]FAPI-74 in detecting and staging PDAC in comparison with current standard of care imaging.
Open AccessHead-to-Head Intra-Individual Comparison of Biodistribution and Tumor Uptake of [18F]FAPI-74 with [18F]FDG in Patients with PDAC: A Prospective Exploratory Study
Background: Radiolabeled fibroblast activation protein (FAP) ligands, a novel class of tracers for PET/CT imaging, have demonstrated very promising results in various oncological, as well as in some benign, diseases with long-term potential to supplant the current pan-cancer agent [18F]FDG in some cancer types. Pancreatic ductal carcinoma (PDAC) belongs to the group of epithelial malignancies with a strong so-called “desmoplastic reaction”, leading to a prominent tumor stroma with cancer-associated fibroblasts that exhibit a marked overexpression of fibroblast activation protein (FAP). The first clinical experiences in PDAC with 68Ga-labeled FAP ligands suggested superior sensitivity to [18F]FDG. However, there is limited data with 18F-labeled FAP derivatives, i.e. [18F]FAPI-74, yet prospective single- and multicenter trials are already ongoing. In this proof-of-concept study, we sought to evaluate the biodistribution, tumor uptake, and lesion detectability in patients with PDAC using [18F]FAPI-74 PET/CT as compared to [18F]FDG PET/CT scans for staging. Methods: This study includes 7 patients (median age 69) who underwent both [18F]FDG PET/CT with contrast-enhancement and [18F]FAPI-74 PET with low-dose CT for primary staging (n = 3) and therapy response control after neoadjuvant (n = 1) or re-staging after palliative therapy (n = 3). The mean interval between PET scans was 11 ± 4 days (range 1–15 days). The [18F]FDG and [18F]FAPI-74 PET/CT scans were acquired at 64 ± 4.1 min (range 61–91 min) and 66.4 ± 6.3 min (range 60–76 min), respectively, after administration of 200 ± 94 MBq (range 79–318 MBq) and 235 ± 88 MBq (range 90–321 MBq), respectively. Quantification of tracer uptake was determined with SUVmax and SUVmean. Furthermore, the tumor-to-background ratio (TBR) was derived by dividing the SUVmax of tumor lesions by the SUVmax of adipose tissue, skeletal muscle, and blood pool. Results: Overall, 32 lesions were detected in 7 patients including primary (n = 7), lung (n = 7), bone (n = 3), lymph node (n = 13), and peritoneal metastases (n = 2). [18F]FAPI-74 detected 22% more lesions compared with [18F]FDG with a better TBR and visual lesion delineation. In one patient the primary lesion could be detected unequivocally with [18F]FAPI-74 but was missed by [18F]FDG imaging. Altogether, most of the lesions demonstrated markedly elevated uptake of [18F]FAPI-74 with a simultaneous lower uptake in the background, providing a very high visual contrast. Conclusion: To the best of our knowledge, this is the first, prospective, intra-individual investigation comparing [18F]FAPI-74 with [18F]FDG imaging in PDAC with encouraging results. These pivotalresults supporta larger, multicentric, prospective study to determine the value of [18F]FAPI-74 in detecting and staging PDAC in comparison with current standard of care imaging.
- Open Access
Intra-Individual Comparison of Physiologic [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 Uptake in Ganglia in Patients with Prostate Cancer: A Retrospective, Monocentric Analysis
Background: Several studies indicate, particularly in the case of [18F]PSMA-1007, a relatively high rate of detection of ganglia in PSMA PET imaging. Ganglia are an integral part of the sympathetic portion of the autonomous nervous system. To date, no studies have directly compared [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 ganglionic uptake intra-individually and analyzed the underlying molecular and physical mechanisms of different detection rates. With this monocentric retrospective study, we sought to evaluate the intra-individual physiological ganglion uptake of these different PSMA ligands in evidence-based imaging for prostate cancer. Methods: Our cohort consists of 19 male patients (median age 72 ± 9 with a range of 56–85) with biochemical recurrence of prostate cancer who underwent both [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 PET/CT in our clinic on the same scanner per standard care between March 2015 and March 2022. Tracer uptake was quantified according to maximum standardized uptake value (SUVmax) for both [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 PET/CT scans. Ganglia-to-background ratios (GBRs) were determined to quantify the image contrast through dividing the SUVmax of the ganglia by the background value (SUVmax of blood pool in the descending aorta, fatty tissue, and skeletal muscle in gluteal region). We used descriptive analyses for demographics and tumor characteristics and performed two-way repeated-measures ANOVA (analysis of variance) for SUV metrics including GBR measurements. Results: In total, we examined 101 ganglia with [18F]PSMA-1007 scanning, localized mostly in pairs as stellate, coeliac, and sacral, of which 76 were also detected with [68Ga]Ga-PSMA-11 PET/CT scanning. There was no statistically significant difference in PSMA uptake in terms of SUVmax between [18F]PSMA-1007 and [68Ga]Ga-PSMA-11 (p value: 0.052). In contrast, the comparison of GBRs revealed a higher detectability rate of ganglia with [18F]PSMA-1007 imaging (p < 0.001). Furthermore, a separate comparison of ganglia with respect to their anatomical location also demonstrated statistically significant differences both within and between [18F]PSMA-1007 and [68Ga]Ga-PSMA-11 PET/CT scans. Conclusion: Given the impression of more accentuated [18F]PSMA-1007 uptake in ganglia compared with 68Ga-labelled counterparts, our study demonstrated that the better detectability of ganglia is not due to more intense [18F]PSMA-1007 uptake by these small structures but to much more favorable physical properties of the radionuclide 18F. The most relevant limitations of our study are its retrospective design and the small patient cohort.
Open AccessIntra-Individual Comparison of Physiologic [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 Uptake in Ganglia in Patients with Prostate Cancer: A Retrospective, Monocentric Analysis
Background: Several studies indicate, particularly in the case of [18F]PSMA-1007, a relatively high rate of detection of ganglia in PSMA PET imaging. Ganglia are an integral part of the sympathetic portion of the autonomous nervous system. To date, no studies have directly compared [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 ganglionic uptake intra-individually and analyzed the underlying molecular and physical mechanisms of different detection rates. With this monocentric retrospective study, we sought to evaluate the intra-individual physiological ganglion uptake of these different PSMA ligands in evidence-based imaging for prostate cancer. Methods: Our cohort consists of 19 male patients (median age 72 ± 9 with a range of 56–85) with biochemical recurrence of prostate cancer who underwent both [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 PET/CT in our clinic on the same scanner per standard care between March 2015 and March 2022. Tracer uptake was quantified according to maximum standardized uptake value (SUVmax) for both [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 PET/CT scans. Ganglia-to-background ratios (GBRs) were determined to quantify the image contrast through dividing the SUVmax of the ganglia by the background value (SUVmax of blood pool in the descending aorta, fatty tissue, and skeletal muscle in gluteal region). We used descriptive analyses for demographics and tumor characteristics and performed two-way repeated-measures ANOVA (analysis of variance) for SUV metrics including GBR measurements. Results: In total, we examined 101 ganglia with [18F]PSMA-1007 scanning, localized mostly in pairs as stellate, coeliac, and sacral, of which 76 were also detected with [68Ga]Ga-PSMA-11 PET/CT scanning. There was no statistically significant difference in PSMA uptake in terms of SUVmax between [18F]PSMA-1007 and [68Ga]Ga-PSMA-11 (p value: 0.052). In contrast, the comparison of GBRs revealed a higher detectability rate of ganglia with [18F]PSMA-1007 imaging (p < 0.001). Furthermore, a separate comparison of ganglia with respect to their anatomical location also demonstrated statistically significant differences both within and between [18F]PSMA-1007 and [68Ga]Ga-PSMA-11 PET/CT scans. Conclusion: Given the impression of more accentuated [18F]PSMA-1007 uptake in ganglia compared with 68Ga-labelled counterparts, our study demonstrated that the better detectability of ganglia is not due to more intense [18F]PSMA-1007 uptake by these small structures but to much more favorable physical properties of the radionuclide 18F. The most relevant limitations of our study are its retrospective design and the small patient cohort.
- 16 December 2021
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 61 (02) , 130-131
Radioiodine Uptake of a Benign Peritoneal Cyst on 131-I Whole-body Scan in a Patient Treated for Papillary Thyroid Cancer
A 52-year-old man presented with newly diagnosed papillary thyroid cancer and rh-TSH-stimulated thyreoglobulin at 0.7 ng/ml during primary radioiodine therapy following total thyroidectomy. Aside from the anticipated intense uptake of 131I in the neck area, an unexpected, solitary, strong focal uptake was detected in projection to the caudo-lateral aspect of the liver on 131I whole-body scan ([Fig. 1]a, arrowhead). On the following SPECT/CT-scan a lesion with an intense accumulation of 131I was detected adjacent to liver segment VI ([Fig. 1]b, arrow). Subsequent abdominal MRI performed 8 weeks after the 131I whole-body-scan showed a small exophytic lesion adjacent to liver segment VI without contrast-enhancement on fat-saturated post-contrast T1-weighted images ([Fig. 2]a, arrowhead) and with high signal on fat-saturated T2-weighted images ([Fig. 2]b, arrowhead). Due to the intense 131I uptake of the lesion, the otherwise unspecific MRI finding was categorized as suspicious of metastasis, and a multidisciplinary tumour board decision was made to resect the lesion. During laparoscopic surgery, the lesion was detected in the peritoneum adjacent to liver segment VI. Histopathologic examination showed a benign cyst ([Fig. 3]) with partial squamous epithelium. Immunohistochemistry was conducted as well, revealing negativity for thyreoglobulin and Thyroid transcription factor-1 (TTF-1), thus excluding metastasis of the known thyroid carcinoma. Solitary metastases to the liver from thyroid cancer are exceptionally rare with 0.5% or less [1], especially in a pT1b tumour, and can present as 131I-negative or positive. 131 I-positive liver metastases from differentiated thyroid cancer are likewise an uncommon occurrence [2]. Radioiodine is a sensitive marker for the detection of thyroid cancer and metastasis. Nevertheless it has a low specificity due to its accumulation in many healthy tissues like thymus, breast, liver, gastrointestinal tract [3]. One of the known mechanisms for radioiodine uptake is the expression of sodium-iodide symporter (NIS) in functioning thyroid tissues [4]. Nevertheless, few cases of unexpected radioiodine uptake in benign tumours have been reported, for example in renal hamartoma [5] or fibroadenoma of the breast [6]. Various cystic structures can also show uptake on radioiodine whole-body-scan, some cases include nabothian cysts [7], functional ovarian cysts [8] or renal cysts [9]. It is assumed that radioiodine enters cysts via passive diffusion or partially active transport and remains trapped due to slow exchange of water and chemicals between the cysts and the surrounding tissue [3]. Nevertheless, focal abdominal uptake of iodine in benign lesions is a rare occurrence and should be further investigated in order to definitively exclude metastasis of the primary. Received: 20 August 2021 Accepted: 15 November 2021 Publication Date: 16 December 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 16 December 2021
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 61 (02) , 130-131
Radioiodine Uptake of a Benign Peritoneal Cyst on 131-I Whole-body Scan in a Patient Treated for Papillary Thyroid Cancer
A 52-year-old man presented with newly diagnosed papillary thyroid cancer and rh-TSH-stimulated thyreoglobulin at 0.7 ng/ml during primary radioiodine therapy following total thyroidectomy. Aside from the anticipated intense uptake of 131I in the neck area, an unexpected, solitary, strong focal uptake was detected in projection to the caudo-lateral aspect of the liver on 131I whole-body scan ([Fig. 1]a, arrowhead). On the following SPECT/CT-scan a lesion with an intense accumulation of 131I was detected adjacent to liver segment VI ([Fig. 1]b, arrow). Subsequent abdominal MRI performed 8 weeks after the 131I whole-body-scan showed a small exophytic lesion adjacent to liver segment VI without contrast-enhancement on fat-saturated post-contrast T1-weighted images ([Fig. 2]a, arrowhead) and with high signal on fat-saturated T2-weighted images ([Fig. 2]b, arrowhead). Due to the intense 131I uptake of the lesion, the otherwise unspecific MRI finding was categorized as suspicious of metastasis, and a multidisciplinary tumour board decision was made to resect the lesion. During laparoscopic surgery, the lesion was detected in the peritoneum adjacent to liver segment VI. Histopathologic examination showed a benign cyst ([Fig. 3]) with partial squamous epithelium. Immunohistochemistry was conducted as well, revealing negativity for thyreoglobulin and Thyroid transcription factor-1 (TTF-1), thus excluding metastasis of the known thyroid carcinoma. Solitary metastases to the liver from thyroid cancer are exceptionally rare with 0.5% or less [1], especially in a pT1b tumour, and can present as 131I-negative or positive. 131 I-positive liver metastases from differentiated thyroid cancer are likewise an uncommon occurrence [2]. Radioiodine is a sensitive marker for the detection of thyroid cancer and metastasis. Nevertheless it has a low specificity due to its accumulation in many healthy tissues like thymus, breast, liver, gastrointestinal tract [3]. One of the known mechanisms for radioiodine uptake is the expression of sodium-iodide symporter (NIS) in functioning thyroid tissues [4]. Nevertheless, few cases of unexpected radioiodine uptake in benign tumours have been reported, for example in renal hamartoma [5] or fibroadenoma of the breast [6]. Various cystic structures can also show uptake on radioiodine whole-body-scan, some cases include nabothian cysts [7], functional ovarian cysts [8] or renal cysts [9]. It is assumed that radioiodine enters cysts via passive diffusion or partially active transport and remains trapped due to slow exchange of water and chemicals between the cysts and the surrounding tissue [3]. Nevertheless, focal abdominal uptake of iodine in benign lesions is a rare occurrence and should be further investigated in order to definitively exclude metastasis of the primary. Received: 20 August 2021 Accepted: 15 November 2021 Publication Date: 16 December 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany